Utidelone pill vs. shot for HER2- advanced breast cancer
Treatments studied
Part of Cancer clinical trials.
This study tests if a new form of the drug Utidelone (given as a capsule) works as well as the current injection for people with HER2-negative advanced breast cancer. It may be an option if you have already had chemotherapy and your cancer is still growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 and no older than 75.
- You have been told that your breast cancer is HER2-negative and it is locally advanced, recurrent, or has spread to other parts of your body.
- You have had at least one type of chemotherapy (taxane or anthracycline) before.
- If your cancer is hormone receptor positive, it has continued to grow despite hormone therapy.
- You have at least one tumor that can be measured on a scan.
- You have not used Utidelone or Capecitabine in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new antibody-based drugs (trastuzumab rezetecan and trastuzumab deruxtecan) designed to treat advanced breast cancer that has spread or cannot be removed with surgery. These drugs target HER2, a protein found on certain cancer cells, and may help patients whose cancer has progressed after previous treatment with trastuzumab and chemotherapy.
This trial tests a chemotherapy drug called utidelone given before surgery to shrink high-risk or locally advanced breast cancer. It may help make surgery more effective.
This trial tests a combination of two chemotherapy drugs, utidelone and capecitabine, for women with HER2-negative breast cancer that has spread to other parts of the body. The goal is to see if this combination can help shrink tumors and slow the cancer's growth.
This trial compares utidelone with docetaxel in people with HER2-negative advanced or metastatic breast cancer. It aims to see which treatment works better and is safer for controlling the cancer and helping patients live longer.
This trial studies whether utidelone combined with bevacizumab can shrink tumors and slow progression in women with advanced HER2-negative breast cancer that has already been treated at least twice. It may help people who have limited options after earlier chemotherapy and/or hormone (endocrine) treatments.
This trial tests if the combination of Utidelone and capecitabine can shrink brain metastases in people with HER2-negative breast cancer. It is designed for those whose cancer has spread to the brain and who have not had many prior treatments.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.